EXCEDE 200 DIN 02360586
Status: Marketed
Holder: ZOETIS CANADA INC
Health Canada record
| Active ingredient(s) | CEFTIOFUR (CEFTIOFUR CRYSTALLINE FREE ACID) 200 MG |
|---|
| Dosage form | Suspension |
|---|
| Route | Intramuscular; Subcutaneous |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Veterinary |
|---|
| ATC | |
|---|
| Original market date | 22-Nov-2011 |
|---|
| Current status date | 02-Sep-2014 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Zoetis Canada Inc — licence 102076, currently licensed, last inspection rating C (2023-10-05).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CEFTIOFUR (CEFTIOFUR CRYSTALLINE FREE ACID)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02305453 | EXCEDE 100 | ZOETIS CANADA INC | Suspension | CEFTIOFUR (CEFTIOFUR CRYSTALLINE FREE ACID) 100 MG | Marketed |
| 02292149 | EXCEDE | ZOETIS CANADA INC | Suspension | CEFTIOFUR (CEFTIOFUR CRYSTALLINE FREE ACID) 200 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 15091 | 2014-01-02 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION (DIN) HOLDER |
| 13679 | 2012-09-28 | Supplement to a New Drug Submission (SNDS) | Change in withholding time |
| 13270 | 2012-05-03 | Supplement to a New Drug Submission (SNDS) | New indications |
| 11939 | 2010-12-20 | New Drug Submission (NDS) | |
Request a quote for EXCEDE 200
How to read a Canadian DIN record